Surgical approach to medullary thyroid carcinoma associated with multiple endocrine neoplasia type 2

Carregando...
Imagem de Miniatura
Citações na Scopus
8
Tipo de produção
article
Data de publicação
2012
Título da Revista
ISSN da Revista
Título do Volume
Editora
HOSPITAL CLINICAS, UNIV SAO PAULO
Citação
CLINICS, v.67, suppl.1, p.149-154, 2012
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
We briefly review the surgical approaches to medullary thyroid carcinoma associated with multiple endocrine neoplasia type 2 (medullary thyroid carcinoma/multiple endocrine neoplasia type 2). The recommended surgical approaches are usually based on the age of the affected carrier/patient, tumor staging and the specific rearranged during transfection codon mutation. We have focused mainly on young children with no apparent disease who are carrying a germline rearranged during transfection mutation. Successful management of medullary thyroid carcinoma in these cases depends on early diagnosis and treatment. Total thyroidectomy should be performed before 6 months of age in infants carrying the rearranged during transfection 918 codon mutation, by the age of 3 years in rearranged during transfection 634 mutation carriers, at 5 years of age in carriers with level 3 risk rearranged during transfection mutations, and by the age of 10 years in level 4 risk rearranged during transfection mutations. Patients with thyroid tumor >5 mm detected by ultrasound, and basal calcitonin levels >40 pg/ml, frequently have cervical and upper mediastinal lymph node metastasis. In the latter patients, total thyroidectomy should be complemented by extensive lymph node dissection. Also, we briefly review our data from a large familial medullary thyroid carcinoma genealogy harboring a germline rearranged during transfection Cys620Arg mutation. All 14 screened carriers of the rearranged during transfection Cys620Arg mutation who underwent total thyroidectomy before the age of 12 years presented persistently undetectable serum levels of calcitonin (<2 pg/ml) during the follow-up period of 2-6 years. Although it is recommended that preventive total thyroidectomy in rearranged during transfection codon 620 mutation carriers is performed before the age of 5 years, in this particular family the surgical intervention performed before the age of 12 years led to an apparent biochemical cure.
Palavras-chave
Carcinoma, Medullary, Multiple Endocrine Neoplasia, Surgery
Referências
  1. Ahmed SR, 2011, J CLIN ENDOCR METAB, V96, P1237, DOI 10.1210/jc.2010-2359
  2. Brandi ML, 2001, J CLIN ENDOCR METAB, V86, P5658, DOI 10.1210/jc.86.12.5658
  3. Carty SE, 2009, THYROID, V19, P1153, DOI 10.1089/thy.2009.0159
  4. Correia-Deur JEM, 2009, CLINICS, V64, P379, DOI 10.1590/S1807-59322009000500002
  5. Costante G, 2011, ONCOLOGIST, V16, P49, DOI 10.1634/theoncologist.2010-0344
  6. de Groot JWB, 2006, ENDOCR REV, V27, P535, DOI 10.1210/er.2006-0017
  7. Eng C, 1996, JAMA-J AM MED ASSOC, V276, P1575, DOI 10.1001/jama.276.19.1575
  8. Eng C, 2010, ANN NY ACAD SCI, V1214, P70, DOI 10.1111/j.1749-6632.2010.05789.x
  9. Erlic Z, 2009, CLIN CANCER RES, V15, P6378, DOI 10.1158/1078-0432.CCR-09-1237
  10. EZABELLA M C L, 1990, Revista do Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, V45, P105
  11. Frank-Raue K, 2006, EUR J ENDOCRINOL, V155, P229, DOI 10.1530/eje.1.02216
  12. Frank-Raue K, 2011, HUM MUTAT, V32, P51, DOI 10.1002/humu.21385
  13. HAYASHIDA CY, 1993, CANCER, V72, P1356, DOI 10.1002/1097-0142(19930815)72:4<1356::AID-CNCR2820720434>3.0.CO;2-0
  14. Hundahl SA, 1998, CANCER, V83, P2638, DOI 10.1002/(SICI)1097-0142(19981215)83:12<2638::AID-CNCR31>3.0.CO;2-1
  15. Kloos RT, 2009, THYROID, V19, P565, DOI 10.1089/thy.2008.0403
  16. Lips CJ, 2005, J INTERN MED, V257, P69, DOI 10.1111/j.1365-2796.2004.01429.x
  17. Lourenco Delmar Muniz Jr, 2007, Clinics (Sao Paulo), V62, P465
  18. Machens A, 2012, CLINICS, V67, P113, DOI 10.6061/clinics/2012(Sup01)19
  19. Machens A, 2009, ANN SURG, V250, P305, DOI 10.1097/SLA.0b013e3181ae333f
  20. Nunes AB, 2002, J CLIN ENDOCR METAB, V87, P5658, DOI 10.1210/JC.2002-020345
  21. Pelizzo MR, 2007, EJSO-EUR J SURG ONC, V33, P493, DOI 10.1016/j.ejso.2006.10.021
  22. Rohmer V, 2011, J CLIN ENDOCR METAB, V96, pE509, DOI 10.1210/jc.2010-1234
  23. Santos Marcelo A C G dos, 2007, Arq Bras Endocrinol Metabol, V51, P1468
  24. Santos Marcelo A C G dos, 2006, Arq Bras Endocrinol Metabol, V50, P7
  25. Schlumberger M, 2012, CLINICS, V67, P125, DOI 10.6061/clinics/2012(Sup01)21
  26. Sherman Steven I, 2007, J Natl Compr Canc Netw, V5, P568
  27. Skinner MA, 2005, NEW ENGL J MED, V353, P1105, DOI 10.1056/NEJMoa043999
  28. Tavares MR, 2008, SURG TODAY, V38, P499, DOI 10.1007/s00595-007-3664-8
  29. Thakker RV, 1998, J CLIN ENDOCR METAB, V83, P2617, DOI 10.1210/jc.83.8.2617
  30. Tincani AJ, DIRETRIZES CLIN SAUD
  31. Toledo RA, 2007, CLIN ENDOCRINOL, V67, P377, DOI 10.1111/j.1365-2265.2007.02895.x
  32. Toledo RA, 2010, J CLIN ENDOCR METAB, V95, P1318, DOI 10.1210/jc.2009-1355
  33. TOLEDO S P A, 1990, Revista do Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, V45, P1
  34. Toledo Sergio Pereira de Almeida, 2006, Clinics (Sao Paulo), V61, P59
  35. Toledo SPA, 2009, CLINICS, V64, P699, DOI 10.1590/S1807-59322009000700015
  36. Wada N, 2003, ANN SURG, V237, P399, DOI 10.1097/00000658-200303000-00015